Department of Obstetrics and Gynecology, Hospital de Cruces, País Vasco University, Baracaldo, Vizcaya, Spain.
Reprod Biomed Online. 2009 Dec;19(6):879-87. doi: 10.1016/j.rbmo.2009.09.016.
This single-centre, randomized, parallel group, comparative study aimed to identify potential benefits of mid-follicular recombinant human LH (r-HLH) supplementation in women aged 35-39 years undergoing ovarian stimulation for intracytoplasmic sperm injection (ICSI). The main endpoint was the number of metaphase II oocytes retrieved. After pituitary suppression with a gonadotrophin-releasing hormone agonist, ovarian stimulation was initiated with recombinant human FSH (r-HFSH; 300-450 IU/day). On stimulation day 6, patients were randomized to receive r-HFSH alone or r-HFSH + r-HLH (r-HLH 150 IU/day) for the remainder of the stimulation period. Final follicular maturation was triggered with 250 mug of recombinant human chorionic gonadotrophin. After assessing oocyte nuclear maturity, oocyte were fertilized by ICSI and afterwards embryo quality was analyzed. Of the 131 women enrolled, 68 were allocated to r-HFSH alone and 63 to r-HFSH + r-HLH. No significant differences were observed in markers of either oocyte or embryo quality or quantity. However, higher rates of implantation and live birth per started cycle were observed with r-HLH supplementation than with r-HFSH alone. Although additional large studies are required to further investigate these findings, r-HLH supplementation for women aged 35-39 years undergoing ICSI is recommended as it may have a beneficial action on implantation.
这项单中心、随机、平行组、对照研究旨在确定在接受胞浆内精子注射（ICSI）的 35-39 岁女性的卵泡中期重组人 LH（r-HLH）补充的潜在益处。主要终点是获得的中期 II 卵母细胞数量。在使用促性腺激素释放激素激动剂抑制垂体后，开始使用重组人 FSH（r-HFSH；300-450IU/天）进行卵巢刺激。在刺激第 6 天，患者被随机分配接受 r-HFSH 单独治疗或 r-HFSH+r-HLH（r-HLH 150IU/天）治疗，直至刺激期结束。用 250 微克重组人绒毛膜促性腺激素触发最终卵泡成熟。评估卵母细胞核成熟度后，通过 ICSI 使卵母细胞受精，然后分析胚胎质量。在纳入的 131 名女性中，68 名被分配接受 r-HFSH 单独治疗，63 名接受 r-HFSH+r-HLH 治疗。在卵母细胞或胚胎质量或数量方面均未观察到显著差异。然而，与 r-HFSH 单独治疗相比，r-HLH 补充治疗后的着床率和活产率更高。尽管需要进一步开展更多的大型研究来进一步研究这些发现，但建议对接受 ICSI 的 35-39 岁女性补充 r-HLH，因为它可能对着床有有益作用。
